Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 461Melanoma 300Squamous Cell Carcinoma of Head and Neck 234Parkinson Disease 4, Autosomal Dominant Lewy Body 189Neoplasms 185Breast Neoplasms 162Triple Negative Breast Neoplasms 161Neoplasm Metastasis 156Lung Neoplasms 146Colorectal Neoplasms 142Carcinoma, Renal Cell 132Head and Neck Neoplasms 123Stomach Neoplasms 104Ovarian Neoplasms 100Carcinoma, Transitional Cell 91Urinary Bladder Neoplasms 81Pancreatic Neoplasms 81Carcinoma, Hepatocellular 74Endometrial Neoplasms 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 49Sarcoma 43Carcinoma 42Glioblastoma 40Carcinoma, Squamous Cell 39Small Cell Lung Carcinoma 38Hodgkin Disease 36Cholangiocarcinoma 35

Interventions

Etoposide 4Carboplatin 4atezolizumab 3pembrolizumab 2Radiotherapy 2tislelizumab 1sintilimab 1irinotecan sucrosofate 1durvalumab 1camrelizumab 1apatinib 1anlotinib 1amrubicin 1Platinum 1Paclitaxel 1Observation 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Epirubicin 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Cancer Extensive Stage × pembrolizumab × Clear all
NCT05745350 2025-02-11

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Recruiting
45 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

NCT03253068 2020-05-19

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Wakayama Medical University

Phase 2 Unknown
25 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡